Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Fresh Tracks Therapeutics, Inc. FRTX NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
53/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Fresh Tracks Therapeutics, Inc. (FRTX) — Analyst outlook / Analyst consensus target is. Based on 1 analyst ratings, the consensus is bullish — 1 Buy.

FRTX Analyst Ratings

Buy
1
Ratings
1 Buy
Based on 1 analysts giving stock ratings to Fresh Tracks Therapeutics, Inc. in the past 3 months
Rating breakdown
Buy
1 100%
100%
Buy
1 analysts
0%
Hold
0 analysts
0%
Sell
0 analysts

People Also View

NUVB
NUVB
Nuvation Bio Inc.
$4.85
+3.19%
 ASMB
ASMB
Assembly Biosciences, Inc.
$29.44
+0.68%
 THRD
THRD
Third Harmonic Bio, Inc.
$5.38
-0.09%
 UNCY
UNCY
Unicycive Therapeutics, Inc.
$6.94
+4.83%
 ACHL
ACHL
Achilles Therapeutics plc
$1.48
+0.68%
 TIL
TIL
Instil Bio, Inc.
$8.44
+1.02%
 SABS
SABS
SAB Biotherapeutics, Inc.
$3.86
-1.03%
 NXTC
NXTC
NextCure, Inc.
$12.77
+3.65%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message